Home » Stocks » Myriad Genetics

Myriad Genetics, Inc. (MYGN)

Stock Price: $13.38 USD 0.31 (2.37%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
Pre-market: $13.11 -0.27 (-2.02%) Aug 14, 8:49 AM

Stock Price Chart

Key Info

Market Cap 997.54M
Revenue (ttm) 760.80M
Net Income (ttm) -199.50M
Shares Out 74.55M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE 12.64
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $13.38
Previous Close $13.07
Change ($) 0.31
Change (%) 2.37%
Day's Open 13.04
Day's Range 12.67 - 13.48
Day's Volume 881,499
52-Week Range 9.24 - 47.10

More Stats

Market Cap 997.54M
Enterprise Value 1.07B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 74.55M
Float 65.48M
EPS (basic) -2.69
EPS (diluted) -2.01
FCF / Share 0.68
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 5.06%
Payout Ratio n/a
Shares Short 10.93M
Short Ratio 13.10
Short % of Float 30.75%
Beta 1.29
PE Ratio n/a
Forward PE 12.64
P/FCF Ratio 19.75
PS Ratio 1.31
PB Ratio 0.96
Revenue 760.80M
Operating Income -234.50M
Net Income -199.50M
Free Cash Flow 50.50M
Net Cash -77.00M
Net Cash / Share -1.03
Gross Margin 85.45%
Operating Margin -30.82%
Profit Margin -31.20%
FCF Margin 6.64%
ROA -2.43%
ROE -14.49%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 1
Overweight 1
Hold 5
Underweight 1
Sell 2

Analyst Consensus: Hold

Price Target

$15.12*
(13.00% upside)
Low
8.00
Current: $13.38
High
30.00
Target: 15.12
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue851744729741723778613496402363
Revenue Growth14.44%2.06%-1.59%2.41%-7.08%26.91%23.63%23.36%10.87%-
Gross Profit650567558583576669534431355318
Operating Income8.7060.7043.20153134274228180158135
Net Income4.6013317.4011780.20176147112101152
Shares Outstanding73.5069.4068.3070.0071.3075.7080.9084.6189.7996.34
Earnings Per Share0.061.850.251.601.082.251.771.301.101.54
EPS Growth-96.76%640%-84.38%48.15%-52%27.12%36.15%18.18%-28.57%-
Operating Cash Flow83.70116106166141190174142131155
Capital Expenditures-8.60-8.40-6.10-5.00-23.90-14.30-11.40-9.41-3.79-7.60
Free Cash Flow75.10108100161117176163132127147
Cash & Equivalents137181151159145186372341346403
Total Debt2349.3099.10-------
Net Cash / Debt-96.6017151.60159145186372341346403
Assets1,5631,1751,209881766824804691611594
Liabilities47420944113210410575.2354.9844.0436.27
Book Value1,089966768748662719729636567558
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Myriad Genetics, Inc.
Country United States
Employees 2,600
CEO R. Bryan Riggsbee

Stock Information

Ticker Symbol MYGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: MYGN
IPO Date October 5, 1995

Description

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.